G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy

BACKGROUND: Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Marcelo Lima, Profitós-Pelejà, Núria, Santos, Juliana Carvalho, Blecua, Pedro, Reyes-Garau, Diana, Armengol, Marc, Fernández-Serrano, Miranda, Miskin, Hari P., Bosch, Francesc, Esteller, Manel, Normant, Emmanuel, Roué, Gael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160608/
https://www.ncbi.nlm.nih.gov/pubmed/37153563
http://dx.doi.org/10.3389/fimmu.2023.1130052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160608/
https://www.ncbi.nlm.nih.gov/pubmed/37153563
http://dx.doi.org/10.3389/fimmu.2023.1130052

Ejemplares similares